Date post: | 17-Jul-2015 |
Category: |
Health & Medicine |
Upload: | biomedcode-hellas-sa |
View: | 186 times |
Download: | 0 times |
MODELING HUMAN INFLAMMATORY CONDITIONS• ACUTE INFLAMMATION• RHEUMATOID ARTHRITIS• SPONDYLOARTHROPATHY• INTESTINAL INFLAMMATION• PSORIASIS• MULTIPLE SCLEROSIS• OSTEOPOROSIS• MOLECULAR & CELLULAR ASSAYS
ANIMAL DISEASE MODELS
DISEASE PHENOTYPING
EFFICACY EVALUATION
1
2
LPS/Dgal in human TNF trasgenic mice (Tg1278TNFko) for the fast in vivo screenining of anti‐hTNF therapeutics.
Read out parameters: Lethality, IL6 levels
Acute Inflammation Model: DGalN/LPS Hepatic failure Model
3
LPS in human TNF trasgenic mice (Tg1278TNFko) for the fast in vivo screenining of anti‐hTNF therapeutics.
Read out parameters: Cytokine and chemokine profiling
Cytokine Cascade
Saline 0.3 1.0 3.0 TNFko
Infliximab (mg/kg)
Acute Inflammation Model: LPS Acute Sepsis Model
Saline 0.3 1.0 3.0 TNFko
Infliximab (mg/kg)
Saline 0.3 1.0 3.0 TNFko
Infliximab (mg/kg)
Mou
se G
M-C
SF (p
g/m
l)
Human TNF transgenic mice
Model TNF Expression Disease
Tg197 soluble & transmembrane hTNF Deregulated Arthritis
Tg3647 soluble & transmembrane hTNF Deregulated Arthritis
Tg5453 transmembrane hTNF Deregulated Arthritis
Human TNF dependent spontaneous models of Arthritis for the preclinical efficacy evaluation of anti‐hTNF therapeutics, kinase inhibitors and others.
Tg5453: transmembrane hTNF dependent fast progressing arthritis
Tg197: soluble and transmembrane hTNF dependent dependent fast progressing arthritis
Tg3647: soluble and transmembrane hTNF dependent slow progressing arthritis
Rheumatoid Arthritis (RA) Models
4
In vivo Arthritis Histopathological Arthritis Pharmacogenomics
Read out parameters : In vivo arthritis, weight measurements, histopathological evaluation
Human TNF dependent spontaneous models of Arthritis for the preclinical efficacy evaluation of anti‐hTNF therapeutics, kinase inhibitors and others.
Rheumatoid Arthritis (RA) Models
5
Human TNF and human TNFR1 dependent spontaneous models of Arthritis for the preclinical efficacy evaluation of anti‐hTNF and antihTNFR1 therapeutics and others
Tg197/hTNFR1KI mice
Read out parameters : In vivo arthritis, weight measurement, histopathological evaluation
Rheumatoid Arthritis (RA) Models
6
CAIA induced in wild type or knock out and mutated mice for the evaluation of therapeutic targets.
Read out parameters : In vivo arthritis, weight measurements, histopathological evaluation
Collagen Antibody Induced Arthritis (CAIA)
CAIA induced in C57BL6/N and C57BL6/J mice The effect of dexamethasone or Enbrel treatment in CAIA induced in C57BL6/J animals
7
CAIA induced in human TNF transgenic mice (Tg1278TNFko) for the preclinical efficacy evaluation of anti‐hTNF and other therapeutics targeting cytokines, kinases and other therapeutic targets.
Read out parameters : In vivo arthritis, weight measurements, histopathological evaluation
J Transl Med. 2014 Oct 25;12(1):285. Collagen II antibody‐induced arthritis in Tg1278TNFko mice: optimization of a novel model to assesstreatments targeting human TNFa in rheumatoid arthritis.
Collagen Antibody Induced Arthritis (CAIA)
8
TNF‐DARE: A spontaneous mTNF‐dependent dual disease mouse model of spondyloarthropathy and intestinal inflammation for the preclinical efficacy evaluation of anti‐TNF and other therapeutics in two pathologies simultaneouslyRead out parameters: In vivo arthritis (grip strength), weight measurements, arthritis and ileitis histopathological evaluation
Salin
eEt
aner
cept
Spondyloarthropathy Disease Model
9
TNBS colitis in human TNF transgenic mice for the preclinical efficacy evaluation of anti‐hTNF therapeuticsRead out parameters: weight measurements, histopathological evaluation, thick organ cultures and cytokine detection
Adal
imum
abSa
line
Intestinal Bowel Disease Model
10
A human RANKL transgenic mouse model (Tg5519) of spontaneous osteoporosis for the evaluation of anti‐hRANKL and other therapeutics.Read out parameters: weight measurements, histopathological evaluation, microCT, biochemical monitoring of bone metabolism
WT Saline Denosumab
H&E
TRAP
Osteoporosis Model
11
Imiquimod (IMQ) induced psoriasis in wild type and human IL17a transgenic mice for the preclinical efficacy evaluation of anti‐hIL17 and other therapeutics.
Normal sk
inIM
Q psoria
tic sk
in
Read out parameters: Skin erythema, skin thickening and scaling, weight measurements, histopathological evaluation.
Psoriasis Model
12
MOG35‐55‐induced Experimental Autoimmune Encephalomyelitis (EAE) in wild type or humanized mouse models for the preclinical efficacy evaluation of anti‐hTNFR1 and other therapeutics.
Read out parameters : weight measurements, in vivo clinical scoring, histopathological evaluation.
Wild type animals hTNFR1KI animals
Multiple Sclerosis Model
13
•Histopathology
•Whole organ cutlure
•Cytokine analysis
•Molecular Assays
•Cellular Assays
•Pharmacogenomics analysis
Ex vivo and In vitro Assays
14
•Generation of transgenic, knock out and humanized animals
•Phenotyping of knock out mice in a disease context
•Novel mouse model development
•Novel assay development
•Pharmacokinetics/Pharmacodynamics
•Customized specimen collection
•Immunohistochemisry
•Pharmacogenomics
Customized Services
15